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ABSTRACT: The tumor suppressor p53 is a hub protein with
a multitude of binding partners, many of which target its
intrinsically disordered N-terminal domain, p53-TAD. Part-
ners, such as the N-terminal domain of MDM2, induce
formation of local structure and leave the remainder of the
domain apparently disordered. We investigated segmental
chain motions in p53-TAD using fluorescence quenching of an extrinsic label by tryptophan in combination with fluorescence
correlation spectroscopy (PET-FCS). We studied the loop closure kinetics of four consecutive segments within p53-TAD and
their response to protein binding and phosphorylation. The kinetics was multiexponential, showing that the conformational
ensemble of the domain deviates from random coil, in agreement with previous findings from NMR spectroscopy.
Phosphorylations or binding of MDM2 changed the pattern of intrachain kinetics. Unexpectedly, we found that upon binding
and phosphorylation chain motions were altered not only within the targeted segments but also in remote regions. Long-range
interactions can be induced in an intrinsically disordered domain by partner proteins that induce apparently only local structure
or by post-translational modification.
■ INTRODUCTION
The tumor suppressor protein p53 is a transcription factor that,
among other functions, up-regulates the expression of genes
involved in cell-cycle arrest, senescence, and apoptosis in
response to cellular stress.
1,2 Its activity is modulated through
key interactions with coactivators that control its stability and
transcriptional output. Repression of p53 activity is importantly
mediated by the interaction of its N-terminal domain, p53-
TAD, with the ubiquitin ligase MDM2.
3 There is competition
for binding the p53-TAD between the N-terminal domain of
MDM2 and coactivators, such as p300, that assist in up-regula-
tion of transcription.
3 p53-TAD consists of two subdomains,
TAD1 (residues 1−40) and TAD2 (41−61), which are essen-
tial for interactions with coactivators.
4,5 On stress-induced
activation, p53-TAD undergoes extensive phosphorylation,
which inhibits the binding to MDM2 and enhances binding
to p300.
6 An array of kinases dynamically phosphorylates serine
and threonine residues throughout the domain, dependent on
the type and dose of damage or stress.
7 The influence of these
post-translational modifications on binding affinity and con-
sequences on p53 activity have been studied intensively using
biochemical methods as well as at the cellular level.
5,6,8−12
Overall phosphorylation modulates p53-TAD interactions with
various binding partners, enhancing transcription protein
contacts and activity.
The isolated p53-TAD is intrinsically disordered.
13−15 Its
hydrodynamic radius in physiological solution is similar to that
of chemically denatured proteins of same sequence length.
14,16
p53-TAD forms local elements of helical structure that become
fully helical on binding to coactivators/repressors.
17−20 Nascent
local structural elements have been detected in subdomains in
isolation, structures that are thought to be dynamic, even in the
context of tight associations with transcription proteins as
shown by NMR.
14,21−25 Further, in the context of intrinsically
disordered domains, phosphorylation can disrupt or stabilize
structure locally, influencing protein function.
18,26,27 However,
the consequences of post-translational modifications on the
structural and dynamic properties of p53-TAD are not well
understood.
p53 is misregulated in >70% of all types of human cancers,
and it has thus been a highly targeted protein for phar-
macological intervention. Further, its structure and function are
representative of a large and important class of transcriptional
activators, and as a result, p53 serves as an exceptional model
for dissecting transcriptional activator binding networks. One of
the prevailing questions for this class of activators is how the
transcriptional activation domains, domains that are intrinsically
disordered in the absence of binding partners, are structurally
altered by post-translational modifications and/or the binding
of partner proteins. For p53, phosphorylation at several posi-
tions is known to alter its binding preference from an
interaction with its repressor protein Mdm2 to the formation
of complexes with coactivators such as CBP/p300.
6 Protein
phosphorylation in disordered proteins (or disordered seg-
ments of proteins) is a very common phenomenon, important
and relevant to different human diseases, and in these cases,
where there is an absence of crystallographic data, the effects of
protein phosphorylation are particularly difficult to understand
from a structural perspective.
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in p53-TAD(1−93) and studied their response to binding of
the N-terminal domain of MDM2(2−125) and site-specific
phosphorylation, using fluorescence quenching by photo-
induced electron transfer (PET) in combination with fluo-
rescence correlation spectroscopy (PET-FCS).
28,29 We found
site-dependent, multiexponential kinetics of loop closure on the
nanosecond to microsecond time scale. MDM2(2−125) dra-
matically altered chain motions in sequence segments directly
involved in binding but also influenced chain motions in
neighboring segments. Phosphorylation of p53-TAD slowed
loop closure of the targeted chain segment. Unexpectedly, we
observed the appearance of additional microsecond kinetics in
chain segments that were remote from the sites of
phosphorylation. Our results indicate allosteric communication
in the mechanism of regulation of p53 through its trans-
activation domain.
■ RESULTS
Design of the Reporter System To Measure Chain
Motions in p53-TAD. PET-FCS measures kinetics of protein
chain motions by correlation analysis of fluorescence
fluctuations arising from individual molecules passing through
the detection volume of a confocal fluorescence microscope
setup by Brownian motion.
28 The side chain of Trp (W)
quenches the fluorescence of extrinsic labels on contact with it
via PET. Fluorescence fluctuations caused by interactions
between fluorophore and Trp within proteins reveal kinetics of
ultrafast folding,
28,29 motions within folding intermediates,
30
and loop closure kinetics within protein denatured states or
intrinsically disordered domains.
16,29 The rate constant of loop
closure is the rate at which two side chains within a polypeptide
form contact, thereby closing a loop. The process is mediated
by diffusional motions of the polypeptide backbone. Here, we
applied PET-FCS to measure loop closure kinetics of segments
within the intrinsically disordered p53-TAD.
p53-TAD contains three Trps that can serve as fluorescence
quenchers in PET-FCS. To probe loop closure kinetics site-
specifically, we replaced two Trp residues by phenylalanine and
used the third as a PET probe. The oxazine fluorphore Atto-
Oxa11 (Oxa) was attached site-specifically to p53-TAD using a
thiol-reactive maleimide-derivative of the fluorophore to modify
single cysteine residues that had been introduced via site-
directed mutagenesis. Residues P13, V31, and P60, which
border the helical and turn regions of TAD1 and TAD2, were
replaced by cysteine.
5,14 The TAD1 and TAD2 tryptophans
W23 and W53 were used as PET probes, while W91 was pre-
sent as a phenyalanine in all constructs. In this way, we
generated four 93-residue p53-TAD(1−93) constructs to mea-
sure the loop closure kinetics of segments Oxa13-W23, W23-
Oxa31, Oxa31-W53, and W53-Oxa60 (Figure 1).
Kinetics of Loop Closure within p53-TAD and
Influence of MDM2 (2−125) Binding. We recorded
autocorrelation functions (ACFs) of all four p53-TAD (1−
93) constructs using FCS to determine rate constants of loop
closure of individual chain segments (Figure 1). We observed
pronounced decays of the ACFs in the submillisecond time
domain reporting on intrachain dynamics. We could exclude
Figure 1. Segmental chain motions in p53-TAD(1−93) and influence of MDM2(2−125) binding. Top: Sequence of p53-TAD(1−93) from the N-
to the C-terminus. The positions where the fluorophore AttoOxa11 has been introduced and where the natural Trp side chains are located to probe
loop closure kinetics are indicated in red and blue, respectively. The four chain segments probed are color-coded at the top of the sequence. The
sequence segment that binds to MDM2(2−125) is indicated by a black bar. Middle: ACFs recorded from modified p53-TAD(1−93) in the free and
MDM2(2−125)-bound states. The probed chain segments are color-coded as illustrated in the top sequence and shown in each panel. The black
lines are data fits to a model for a single diffusing species exhibiting up to three monoexponential relaxations. ACFs of segments 13−23 and 23−31
without MDM2(2−125) are offset along the y-axis for reasons of clarity. Bottom: Plots of the amplitudes of each of the monoexponential
submillisecond decays versus the corresponding rate constant of loop closure, kic, calculated from the fitted parameters (Materials and Methods).
The color code from the panels above applies. The arrows indicate the observed changes in amplitude and rate constant of the individual relaxations
upon MDM2(2−125)-binding. Arrows from or to the zero-line of amplitude (x-axis) indicate the appearance or disappearance, respectively, of a
relaxation. Error bars are propagated standard errors from data fits.
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second relaxations in PET-FCS experiments because the label is
devoid of photophysical effects under the employed exper-
imental conditions.
29,30 The submillisecond decays did not fit
to a single-exponential function but instead required an FCS
model containing a sum of two single-exponential decays
(Materials and Methods). The kinetics varied with sequence
position. There was a dominant ∼100-ns kinetic phase and a
microsecond phase of minor amplitude present in all constructs
(Figure 1). While the nanosecond-decays reported loop
closure, the microsecond relaxations originated from the for-
mation of nonrandom chain configurations that modulate
kinetics of chain contacts between fluorophore and Trp. All rate
constants of loop closure determined by PET-FCS are
summarized in Table 1. The microsecond rate constant and
corresponding amplitude of Oxa13-W23 were within the
experimental error limits of the major phase and could not
be determined accurately.
To monitor changes in each of the observed phases upon
induced structure formation, we investigated the influence of
MDM2(2−125) binding on loop closure kinetics. The effects
of the p53-TAD(1−93) tryptophan mutations on MDM2(2−
125) binding affinity were measured in independent isothermal
titration calorimetry (ITC) experiments (Supporting Informa-
tion Figure 1). Although the W53F mutation did not cause
significant changes in affinity, a decreased affinity was observed
for the W23F mutant, likely due to its direct participation in the
MDM2(2−125) binding interaction. For this mutant, the
binding affinity was determined to be approximately 10-fold
weaker than the wild-type interaction measured by tryptophan
fluorescence (Supporting Information Figure 2). To overcome
problems from differences in affinity, we performed all PET-
FCS experiments under saturating conditions (excess of 50 μM
MDM2(2−125) over 1 nM p53-TAD(1−93)), where p53-TAD-
(1−93) was near-quantitatively bound to MDM2 (2−125).
Recorded ACFs of MDM2(2−125)-binding experiments and
data analysis are shown in Figure 1. The primary MDM2(2−
125) binding site within the p53-TAD(1−93) spans segments
Oxa13-W23 and W23-Oxa31, while weaker influences are
reported in the neighboring Oxa31-W53 and the remote W53-
Oxa60 segments.
21 We observed a substantial decrease in
amplitude of motions within segments directly involved in
MDM2(2−125) binding, i.e. Oxa13-W23 and W23-Oxa31.
Accordingly, rate constants of loop closure slowed from the
∼100-ns to the microsecond time scale. There was evidence for
residual chain motions in segments directly involved in MDM2
binding from the presence of submillisecond PET-FCS decays.
The nanosecond loop closure kinetics in segments remote from
the primary MDM2(2−125) binding site, i.e. Oxa31-W53 and
W53-Oxa60, were unaffected. But, there were significant
changes in the microsecond chain motions of these remote
segments upon MDM2(2−125) binding: The amplitude of the
microsecond kinetic phases of Oxa31-W53 and W53-Oxa60
increased, and an additional, slow ∼100-μs phase appeared in
both segments. We also attempted to evaluate binding of p53-
TAD(1−93) to the Taz1 domain of p300, which was not
influenced by any of the tryptophan mutations. However, com-
plex kinetics was observed including the appearance of new
microsecond phases that could not be fitted to simple
exponentials. The origin of this complex kinetics remained
unclear but most likely arose from the presence of multiple
binding sites in p53-TAD that recognize the Taz1 domain of
p300. A binding equilibrium as origin of complex kinetics can
be ruled out because the dissociation constant of the interaction
is in the nanomolar range, and experiments were carried out
under saturating conditions, i.e. μM p300-Taz1.
Effects of Phosphorylation on Chain Motions within
p53-TAD(1−93). Enzymatic phosphorylation of sites S33, S46,
and T81 did not induce any significant global structural changes
in p53-TAD(1−93) as judged by far-UV CD spectroscopy
(Figure 2). p53-TAD(1−93) displays the spectral characteristics
of a random coil, with the CD spectrum recorded after
phosphorylation virtually superimposable on that of the wild-
type p53-TAD (1−93). But, in PET-FCS experiments,
phosphorylation of p53-TAD(1−93) influenced intrachain
Table 1. Rate Constants of Loop Closure in p53-TAD
(1−93) and Influence of MDM2(2−125) Binding and
Phosphorylation
a
k1 (×106 s−1) k2 (×105 s −1) k3 (×104 s −1)
Oxa13-W23 2.81 ± 0.46 --
Oxa13-W23
+ MDM2
0.30 ± 0.12
Oxa13-W23-
phos
2.27 ± 0.40 1.3 ± 0.7
Oxa13-W23-
phos + MDM2
-- 4 ± 2
W23-Oxa31 3.24 ± 0.83 3.9 ± 1.7
W23-Oxa31
+ MDM2
0.64 ± 0.50 4.5 ± 0.8
W23-Oxa31-
phos
1.9 ± 0.6 3.1 ± 1.5
W23-Oxa31-
phos + MDM2
n.d. n.d. n.d.
Oxa31-W53 1.39 ± 0.47 7.5 ± 4.9
Oxa31-W53
+ MDM2
2.1 ± 1.1 2.2 ± 0.5 0.58 ± 0.25
Oxa31-W53-
phos
2.6 ± 0.9
Oxa31-W53-
phos + MDM2
1.01 ± 0.24 0.43 ± 0.12 0.11 ± 0.06
W53-Oxa60 3.59 ± 0.52 2.8 ± 2.7
W53-Oxa60
+ MDM2
4.20 ± 0.72 2.8 ± 0.9 1.13 ± 0.30
W53-Oxa60-
phos
3.33 ± 0.73 1.7 ± 1.5
W53-Oxa60-
phos + MDM2
10 ± 5 1.1 ± 0.4 0.53 ± 0.27
a“--“: Experimental error larger than value. n.d.: Not determined because
of protein aggregation. Errors are standard errors from data fits.
Figure 2. Far-UV CD spectra of 10 μM p53-TAD(1−93) before
(black) and after (gray) phosphorylation of residue side chains S33,
S46, and T81 at 15 °C.
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amplitude of the nanosecond relaxation and correspondingly
slower loop closure of segment Oxa31-W53, which contains two
phosphorylation sites. The microsecond relaxation in the same
segment vanished. Likewise, the amplitude and rate constant of
loop closure in the neighboring segment, W23-Oxa31, dropped.
Significant changes in loop closure kinetics were also observed in
the nanosecond kinetics of segments W53-Oxa60 and Oxa13-
W23 (Figure 3), with the latter one remote from sites of
phosphorylation. All rate constants of loop closure and
corresponding values of phosphorylated p53-TAD(1−93) are
summarized in Table 1.
■ DISCUSSION
The p53-TAD(1−93) is largely unfolded, exhibiting character-
istics of a randomly coiled polypeptide. But, the distinct
elements of secondary structure visible by NMR spectroscopy
in both free and bound p53-TAD(1−93) suggest the presence
of dynamic local structure.
14,22 Energy transfer experiments and
correlation analysis have been used to study the fluctuations in
unstructured proteins to reveal hetererogeneous flexibility and
dynamics often invisible by conventional bulk spectroscopic
methods.
15,31,32 The PET-FCS data with p53-TAD(1−93)
presented here show that although the p53-TAD(1−93) is
flexible, it exhibits significant deviations from random coil
behavior in isolation as well as in the presence of MDM2(2−
125) binding. The rate constants of loop closure in p53-
TAD(1−93) of (1.4−3.6) × 106 s−1 measured for 7−22 residue
loop segments were comparable with those measured within
the denatured state of a natural protein domain.
16,29 But,
noninteracting Gaussian chains exhibit purely monoexponential
rate constants of contact formation between distinct sites
within the chain.
33,34 Loop closure kinetics measured for p53-
TAD deviated from those expected for a Gaussian chain, since
their description required a biexponential decay function. The
second exponential, therefore, provided evidence for the
presence of nonrandom chain configurations populated within
the ensemble of p53-TAD(1−93) conformations, consistent
with an earlier single-molecule FRET study.
15 The time
constant of the second relaxation was slower than nanoseconds,
i.e. on the microsecond time scale, and of smaller amplitude.
However, the amplitude of the microsecond relaxation was
largest in W23-Oxa31, the segment that has nascent helical
structure,
14,22 and is directly involved in MDM2(2−125)
binding.
20 Nanosecond to microsecond structural fluctuations
in other disordered domains have previously been uncovered
by FRET experiments in combination with FCS.
32,35
Previous NMR studies identified helical propensities of
∼30% for residues 22−25,
14 coinciding with the significant
microsecond relaxation in segment W23-Oxa31 observed here.
The result suggests this local helical structural element
fluctuates at ∼3 μs and corroborates the presence of nascent
structure within the chain segment of p53 that is directly involved in
MDM2(2−125) binding. We further identified microsecond
relaxations of small but significant amplitude in segment Oxa31-
W53 that revealed previously unidentified, nonrandom structural
fluctuations at that site.
PET-FCS showed residual mobility of chain segments
directly bound to MDM2(2−125). The finding is in agreement
with results from NMR studies with MDM2(2−125) and the
same chain segments bound to domains of p300, and with peak
disappearance due to resonance broadening.
19,21,23 MDM2(2−
125) binding also caused significant changes in the kinetic
pattern of loop closure of segments remote from the primary
Figure 3. Segmental chain motions in p53-TAD(1−93) and influence of phosphorylation. Top: Sequence as shown in Figure 1. The sites of
enzymatic phosphorylation are indicated in bold and as black dots. Middle: Autocorrelation functions (ACFs) recorded from modified p53-TAD(1−
93) with and without side chains S33, S46, and T81 phosphorylated. The probed chain segments are color-coded as illustrated in the top sequence
and shown in each panel (phosphorylation is indicated as P). The black lines are data fits to a model for a single diffusing species exhibiting up to two
monoexponential relaxations. ACFs of the nonphosphorylated constructs are offset along the y-axis for reasons of clarity. Bottom: Plots of the
amplitudes of each of the monoexponential submillisecond decays versus the corresponding rate constant of loop closure, kic, calculated from the
fitted parameters (Materials and Methods). The color code from the panels above applies. The arrows indicate the observed changes in amplitude
and rate constant of the individual relaxations upon phosphorylation. An arrow to the zero-line of amplitude (x-axis) indicates the disappearance of a
relaxation. Error bars are propagated standard errors from data fits.
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segments of p53-TAD(1−93) amplified microsecond relaxa-
tions in the neighboring segments as judged by their increased
amplitude, indicating enhancement of structural heterogeneity.
The additional kinetics may result from weak interactions
between TAD2 and MDM2(2−125) or induced structural
changes that alter p53 flexibility in this region.
5,21 The bound
complex thus appears to deviate from a classical lock/key-type
rigid body interaction between two proteins, suggested by the
traditional structure−function relationship, but instead exhibits
dynamic character and structural malleability.
Cellular stress caused by DNA damage triggers a cascade of
phosphorylation events in p53 that modulate binding of coacti-
vators and repressors and results in the stabilization and
accumulation of p53, leading to cell-cycle arrest and
apoptosis.
3,7 This multisite phosphorylation has recently been
suggested to act as a rheostat enhancing p53 binding to partner
proteins in an additive manner.
10 Each phosphorylation
introduces two negative charges at the site of modification
that can directly enhance or diminish interactions within a
binding interface by local electrostatic and steric effects. But it is
difficult to rationalize how phosphorylation can modulate
activity in chain segments remote from the site of phos-
phorylation. This effect is, in particular, puzzling if the post-
translational modification takes place in a largely unfolded
protein domain that is expected to lack significant intrachain
interactions. Here, we showed that multisite p53-TAD(1−93)
phosphorylation has both direct as well as remote effects on
p53 flexibility, which are likely to influence p53 regulatory
protein interactions. We found slowed kinetics of loop closure
in segments 23−31 and 31−53 upon phosphorylation of sites
S33, S46, and T81. These changes could arise from repulsive
electrostatic forces introduced by negative charges: S33 is in a
local neighborhood to V31, which has been modified to contain
the fluorophore. The slower kinetics for the 31−53 segment
likely reflected the presence of the additional phosphorylation
on S46 between V31 and W53. But, we also found allosteric
effects in the modulation of chain motions in segments remote
from these phosphorylation sites. The amplitudes of loop
closure kinetics between residues 13/23 and 53/60 dropped
significantly upon phosphorylation of S33, S46, and T81. A
decrease in amplitude can be interpreted microscopically. The
PET-FCS amplitude a equals kc/ko. kc is the microscopic rate
constant of loop closure, and ko is the microscopic rate constant
of dissociation of the looped chain segment. The rate constant
of loop closure of segments 13−23 and 53−60 remained
constant, within error. Therefore, the observed decrease of a
reflected an increased rate constant of loop dissociation. The
observed effects are difficult to rationalize by repulsive
electrostatic interactions introduced by negative charges.
Segments 13−23 are close to the N-terminus and outside the
sequence area where phosphorylation occurs. Changes in loop
closure kinetics can be explained by the presence of transient
interaction networks, as evident from the nascent structure in
the MDM2(2−125)-binding segment discussed above. In-
dications for structural changes upon phosphorylation of p53-
TAD have been found by Stern−Volmer analysis in Trp
fluorescence experiments.
36 Fluctuating long-range interactions
within p53-TAD(1−93) seem to transmit local structural
changes to remote sites within each TAD subdomain,
manifested in changes in loop closure kinetics. The trans-
mission of local structural changes, induced through phosphor-
ylation, through transient interaction networks to remote sites
within this disordered domain, extends the effector potential of
such modifications from local to global.
■ MATERIALS AND METHODS
Protein Synthesis and Purification. The p53(1−93) plasmid
containing a His6/lipoyl tag has been described previously.
23 Briefly,
wild type and mutant His6/lipoyl-tagged p53(1−93) was transformed
into C41 cells and grown to an OD of 0.8 before addition of IPTG and
induction for 16 h at 22 °C. The cells were pelleted and lysed in 50 mM
phosphate 200 mM NaCl, 10 mM imidazole pH 7.5 and run on a
nickel affinity column. The his lipoyl tag was cleaved with thrombin
along with dialysis into 50 mM phosphate 200 mM NaCl pH 7.5. It
was applied to a second nickel column and subsequently run on a
POROS S. Relevant fractions were concentrated and run on a Superdex
30 gel filtration column. Site directed mutagenesis (Stratagene) was
used to generate the phenylalanine and cysteine mutants, and the mutants
were purified in a similar manner as the wild type protein. Human
MDM2(2−125) was purified as described previously.
23
Phosphorylation of p53 (1−93). To generate phosphorylated
material, approximately 1 mL of 1 mM wild type or mutant p53(1−
93) was submitted to multiple rounds of phosphorylation in reactions
consisting of 100 ng of JNK2α (Millipore) in 25 mM Tris pH 7.4,
150 mM NaCl, 1 mM DTT, 0.2 mM EGTA, 10 mM MgCl2, EDTA-
free protease inhibitors (Roche). After phosphorylation, wild type or
mutant p53(1−93) was further purified on a C18 column using
reverse phase HPLC (Waters 600E) and gel filtration on a Superdex
30 column. The correct molecular weight was confirmed using
MALDI mass spectrometry on an Applied Biosystems Voyager DE-RP
MALDI TOF mass spectrometer. Phosphorylation of S33, S46, and
T81 by JNK2α has been confirmed in NMR experiments.
Protein Labeling. To label the cysteine mutants, approximately
1 mL of 150 μM p53 (1−93) was buffer exchanged into 20 mM Tris
pH 7.0 and incubated with 10 mM TCEP and 0.5 mg of AttoOxa11
maleimide or 7-diethylamino-3-(4′-maleimidylphenyl)-4-methylcou-
marin (CPM) (in 20 μL acetonitrile) overnight at 4 °C. Excess
fluorophore was removed by buffer exchange before purification on a
C18 column using a linear 20−70% 0.1%TFA/CH3CN gradient on a
Waters 600E HPLC system. Samples were dialyzed overnight at 4 °C
in 50 mM MES pH 6.8, 100 mM NaCl, 2.5 mM DTT at 25 °C before
PET-FCS experiments.
Circular Dichroism. CD spectra of wild type and phosphorylated
p53 (1−93) were performed on a Jasco J-815 CD spectrometer.
Samples were dialyzed overnight in 25 mM phosphate pH 6.8, 50 mM
NaCl, 1 mM DTE. p53(1−93) (10 μM) was equilibrated for 5 min at
15 °C in a 1 cm quartz glass cuvette before the spectra were taken with
the following parameters: 1 nm band-pass, 1 nm increment, 1 s
integration, 25 nm/min scan speed. The final spectrum was smoothed
using the Savitsky-Golay algorithm (11 points) in the Jasco Spectra
Manager software.
PET-FCS Experiments. PET-FCS experiments were performed on
a home-built confocal fluorescence microscope setup consisting of a
Nikon Eclipse TE2000-U microscope body equipped with a high
numerical aperture objective lens (Nikon, Plan Apo VC 60x/1.40 oil)
and a He−Ne laser at 633 nm (Melles Griot) as excitation source. The
temperature was adjusted to 25 °C using a custom-built objective-type
heater. The excitation power was adjusted to 400 μW, low enough to
prevent photophysical fluorescence fluctuations in the ACFs, using a
neutral density filter. The fluorescence signal of the sample was
optically and spatially filtered using a dichroic mirror (Semrock,
BrightLine FF 494/540/650), a 150 μm pinhole, and a long-pass
cutoff filter (Semrock, RazorEdge 647 nm). A 50% cubic, non-
polarizing beam splitter (ThorLabs) was used to partition photons
between two fiber-coupled avalanche photodiode detectors (Perkin-
Elmer, SPCM-AQR-15-FC), overcoming detector dead-time and after-
pulsing effects. ACFs were recorded in the cross-correlation mode
using a digital hardware correlator device (Flex02-01D, Correlator.-
com). Sample/glass surface interactions in LabTek sample chambers
(Nunc) were suppressed by surface passivation using poly-L-lysine
hydro bromide (Sigma), together with the use of 0.3 mg/mL BSA and
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labeled protein.
PET-FCS Data Analysis. ACFs were fitted to a model for a single
molecule diffusing in two dimensions and exhibiting independent
chemical relaxations described as a sum of single-exponential decays:
37
τ= + τ τ + ∑ − τ τ −− GN a () ( 1 / ) ( 1 e x p ( / ) ) 1
D
1
ii , o b s (1)
τ is the lag time, N denotes the average number of molecules in the
detection focus, τD is the observed diffusion time constant, and ai and
τi,obs denote the amplitude and the observed time constant of the ith
relaxation. A two-dimensional diffusion model was of sufficient
accuracy, since the horizontal dimensions (x, y) of the detection
focus were much smaller than the lateral (z) one. ACFs shown in
figures were normalized to N for reasons of clarity. Rate constants of
loop closure, ki, were calculated from ai and τi,obs assuming a two-state
equilibrium between an open, fluorescent (o) and a closed,
fluorescence-quenched (c) conformation:
= ak k / ic o (2)
τ =+ kk 1/( ) i,obs c o (3)
ko denotes the microscopic rate constant of loop dissociation and kc =
ki denotes the microscopic rate constant of loop closure.
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